Last reviewed · How we verify

NCT04661293: AMDC

Expanded Access Program for Autologous Muscle Derived Cells (AMDCs)

TEMPORARILY NOT AVAILABLE Last updated 13 February 2026
What this trial tests

trial testing Autologous Muscle Derived Cells (AMDCs). Temporarily not available.

Quick facts

Lead sponsorCook MyoSite
StatusTEMPORARILY NOT AVAILABLE
Study typeEXPANDED_ACCESS
Sites1 location across United States

Drugs / interventions tested

Sponsor

Cook MyoSite — full company profile →

Who can join

Eligibility, any sex. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an expanded access program (EAP) for eligible participants designed to provide access to autologous muscle derived cells (AMDCs). Treating physicians may submit requests for expanded access to Cook MyoSite's investigational product by email to MYO-ExpandedAccess@CookMyoSite.com.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cook MyoSite trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04661293.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing